Tag: precision medicine
Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. This approach will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people. It is in contrast to a “one-size-fits-all” approach, in which disease treatment and prevention strategies are developed for the average person, with less consideration of the differences between individuals.
Researchers at WID with expertise in complex biological systems, epigenetics, data science, health care, gene editing, and tissue engineering will contribute to “healthy people” initiatives through precison medicine.
Precision medicine is an important component of WID’s Multi-Omics Hub.
Revolutionary Engineered Blood Vessels Behave Like the Real Thing
WID’s Tom Turng envisions a future in which surgeons can order mass-produced artificial blood vessels that arrive ready to use in bypass surgeries.
WID Seeks Machine Learning and “Fluxomics” Hires
WID seeks to add to its roster of excellent faculty with two new hires in emerging cutting-edge fields.
WID Hubs Launch at Illuminating Connections Event
WID’s new hubs—Data Science, Multi-Omics, and Illuminating Discovery—represent a new path forward for collaborative research projects and fields.
New Technology for Controlling Neural Tissue Manufacturing
A paper published in eLife this week by an interdisciplinary team at WID describes new methods for reproducibly manufacturing brain and spinal cord organoids with strict control over morphogenic and developmental processes.
UW–Madison Researchers Developing Methods to Edit Genes in Brain Cells
A second WID-led team joins NIH’s Somatic Cell Genome Editing Consortium with a grant to study new methods of delivering the CRISPR/Cas9 system to the brain.
Molly Carroll
Application of computational models to predict cancer prognostics from proteomics and secretomics
Micah Dombroe
Lab Manager
Genomic DNA sequencing and viral production. Facilitate various administrative functions.
Xianghui Xu
Research Scientist
Bioinspired macromolecular and supramolecular strategy for advanced biomaterials.
WID Researchers Looking to the Future with UW2020 Awards
Investigators from WID are among the recipients of the latest round of UW2020 awards.
Ryan Aturaliya
Treating ePTFE grafts to mimic the characteristics of human blood vessels.
Jo Handelsman
WID Director
Genetic and biochemical processes underlying interactions within plant and human microbiomes.
UW Carbone Scientists Present at Annual Cancer Research Conference
One of the UW Carbone Cancer Center members presenting is WID’s Peter Lewis. His work focuses on how genes are turned on and off during embryonic development, and how misregulation in those genes can lead to some childhood cancers.
Small But Mighty: Nanoparticles Can Deliver More Types of Drugs, More Safely
WID researcher Shaoqin Sarah Gong is working to more safely deliver a variety of drugs to treat cancer, heart disease and even blindness.
New Hope for Stopping an Understudied Heart Disease in its Tracks
Biomedical engineering professor and Discovery Fellow Kristyn Masters and colleagues identified the early stages of a process that may eventually cause aortic stenosis, a severe narrowing of the aortic valve that reduces blood flow to the body and weakens the heart.
Randolph Ashton Continues Research into Causes of Lou Gehrig’s Disease
In August 2017, Randolph Ashton received almost $800,000 from the National Institute of Neurological Disorders and Stroke, part of NIH, to continue a five-year research study of Lou Gehrig’s disease (amyotrophic lateral sclerosis, or ALS), after successfully completing its first phase.
UW-Madison to be Partner in Center for Cell Manufacturing Technologies
The National Science Foundation has awarded nearly $20 million to a consortium of universities to support a new engineering research center that will develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells. Several WID investigators are collaborators on the project.
Louise Saraspe
In vitro modeling of CAR T cell cytotoxicity, activation, and exhaustion
